NCT03219476View on ClinicalTrials.gov

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2017

Primary Completion Date

February 4, 2020

Study Completion Date

March 20, 2025

Conditions

Breast CancerInvasive Breast Cancer

Interventions

DRUG

Anastrozole

1 mg once daily.

DRUG

Letrozole

2.5mg once daily.

DRUG

Exemestane

25 mg once daily.

DRUG

Tamoxifen

20 mg once daily.

Trial Locations (1)

53226

Froedtert Hospital, Milwaukee

All Listed Sponsors

lead

Medical College of Wisconsin

OTHER

NCT03219476 - Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | Biotech Hunter | Biotech Hunter